Erucalix is a next-generation patented formulation designed to support bone metabolism and actively counteract the processes leading to bone mass and quality loss, typical of osteoporotic conditions.
Thanks to its multifactorial action, Erucalix promotes osteoblast maturation, stimulates the mineralization of newly formed bone, and inhibits the activity of osteoclasts, which are responsible for bone resorption.
Preclinical tests using Transwell® technology highlighted high cellular vitality and the ability to cross the intestinal barrier without compromising its integrity, while contributing to a reduction in oxidative stress.
Action: modulation of bone remodeling.
Target organs: bones
After the selection and development phase, Erucalix underwent rigorous scientific testing. The behavior of the compound was analyzed after being metabolized by intestinal cells. Its effect was then examined on a bone cell line to simulate osteoporotic conditions in vitro and directly observe its action on bone remodeling.
The activity on bone remodeling was evaluated by measuring alkaline phosphatase, a key enzyme in the early phase of osteoblastic differentiation, promoting calcium deposits in the bone matrix.
This innovative blend represents a promising and validated solution for managing bone mineralization. Its benefits derive from a targeted selection of ingredients and thorough testing.
Please note that this website is not aimed at consumers as the information herein contained does not make reference to finished products; the website is available for various countries all over the world and hence it may contain statements or product classification not applicable to your country.